Lara H El Touny
Overview
Explore the profile of Lara H El Touny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun Y, Jenkins L, El Touny L, Zhu L, Yang X, Jo U, et al.
Sci Adv
. 2025 Jan;
11(2):eads2919.
PMID: 39792662
DNA-protein cross-links (DPCs) are among the most detrimental genomic lesions. They are ubiquitously produced by formaldehyde (FA), and failure to repair FA-induced DPCs blocks chromatin-based processes, leading to neurodegeneration and...
2.
El Touny L, Hose C, Connelly J, Harris E, Monks A, Dull A, et al.
Oncotarget
. 2021 Oct;
12(21):2114-2130.
PMID: 34676045
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all...
3.
Aprelikova O, Chen K, El Touny L, Brignatz-Guittard C, Han J, Qiu T, et al.
Clin Epigenetics
. 2016 Apr;
8:38.
PMID: 27081402
Background: Oncogene overexpression in primary cells often triggers the induction of a cellular safeguard response promoting senescence or apoptosis. Secondary cooperating genetic events are generally required for oncogene-induced tumorigenesis to...
4.
El Touny L, Vieira A, Mendoza A, Khanna C, Hoenerhoff M, Green J
J Clin Invest
. 2013 Dec;
124(1):156-68.
PMID: 24316974
Breast cancer (BC) can recur as metastatic disease many years after primary tumor removal, suggesting that disseminated tumor cells survive for extended periods in a dormant state that is refractory...
5.
Chu I, Lai W, Aprelikova O, El Touny L, Kouros-Mehr H, Green J
PLoS One
. 2013 Apr;
8(4):e61125.
PMID: 23577196
Transforming growth factor (ß1TGFß1) can promote proliferation in late stage cancers but acts as a tumor suppressor in normal epithelial cells and in early stage cancers. Although, the TGFß pathway...
6.
El Touny L, Henderson F, Djakiew D
Rejuvenation Res
. 2010 Sep;
13(5):527-37.
PMID: 20818983
Following spinal cord injury (SCI) or peripheral neuropathy, increased levels of the p75(NTR) death receptor initiate the signal transduction cascade leading to cell death. Investigations of compounds that may ameliorate...
7.
Barkan D, El Touny L, Michalowski A, Smith J, Chu I, Davis A, et al.
Cancer Res
. 2010 Jun;
70(14):5706-16.
PMID: 20570886
Breast cancer that recurs as metastatic disease many years after primary tumor resection and adjuvant therapy seems to arise from tumor cells that disseminated early in the course of disease...
8.
El Touny L, Banerjee P
Cancer Res
. 2009 Apr;
69(8):3695-703.
PMID: 19351854
Considered a chemopreventive agent, the ability of genistein to modulate the progression of existing prostate cancer (CaP) is not clear. We show here that the consumption of genistein (250 mg/kg...
9.
El Touny L, Banerjee P
Biochem Biophys Res Commun
. 2007 Jul;
361(1):169-75.
PMID: 17658479
Previous studies demonstrated a direct correlation with loss of kangai-1 (KAI1), a metastasis suppressor, and poor prognosis in human prostate and other cancers. In this study, we have characterized the...
10.
Chau M, El Touny L, Jagadeesh S, Banerjee P
Carcinogenesis
. 2007 Jul;
28(11):2282-90.
PMID: 17615260
Telomerase contributes to the infinite replicative potential of cancer cells by conferring proliferation and survival through the regulation of growth factors and apoptotic proteins. Although it is generally known that...